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 There is a dearth of knowledge and studies 
about empiric antibiotic treatment for 
Extended Spectrum-β-Lactamase (ESBL) 
bacterial pneumonia.1
 This study is meant to improve quality of 
evidence to “medium” levels  from the 
current level of “very-low” quality.1 
 Improved methods for treating Klebsiella 
Pneumoniae infection.
 Primary outcome: Mortality
 Aim: To assess differences in patient 
survival probability due to different 
antibiotic regimens, considering all classes 
of antibiotics.
 Population: People hospitalized with 
Klebsiella Pneumoniae or ESBL-type 
antibiotic resistant gram-negative bacterial 
pneumonia.
 Data source: Electronic medical record data 
from the HealthFacts database (de-identified 
data from 700 Cerner hospitals).
 Statistical Analysis: 
• Forward/backward model selection were 
used to find statistically significant factors.
• Cox Proportional Hazard Models were 
used to determine the Hazard Ratios of 
Klebsiella and ESBL Pneumonia and their 
survival probability. 
• We adjusted for the effects of antibiotic 
resistance(s), antibiotic allergies, age,  
organ failure, severity of illness, 
mechanical ventilation, sepsis, and 
previous aminoglycoside use.
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Census 
Division Pneumonia ESBL %ESBL
1 82668 54 0.07
2 245721 102 0.04
3 80747 21 0.03
4 151255 230 0.15
5 96526 332 0.34
6 251687 217 0.09
7 98559 127 0.13
8 44061 4 0.01
9 162913 905 0.56
Table 3: ESBL among Pneumonia cases by Census Division (Overall and for Klebsiella Pneumoniae)
Figure 4: Glycopeptide antibiotics are associated with a 
significant increase in patient mortality from ESBL 
pneumonia 
Figure 1: Nitrofurans are associated with a large 
significant reduction in mortality from ESBL pneumonia
Table 2: Effect of classes of antibiotics on patient 
survival from K. Pneumoniae infection
 For Klebsiella Pneumoniae infections prior 
treatment with aminoglycosides improves 
patient survival by ≈14% suggesting that 
aminoglycosides are a potential empiric therapy 
for Klebsiella Pneumoniae.
 For ESBL resistance, nitrofurans such as 
nitrofurantoin are associated with ≈12% 
increase in survival. There was insufficient data 
to evaluate Fosfomycin and beta-lactamase 
inhibitor + antibiotic combinations.
 Our analysis has yielded evidence of moderate 
quality for inclusion into treatment guidelines.
Census 
Division K. Pneumoniae ESBL Carb_res %ESBL %Carb_res
1 573
2 1311
3 443
4 1334 2 0.15
5 400 37 1 9.25 0.25
6 2535 13 2 0.51 0.08
7 558
8 237
9 1242 29 4 2.33 0.32
 
   
Table 1: Effect of classes of antibiotics on patient 
survival from ESBL Pneumonia 
Figure 2: Polypeptide antibiotics (e.g. Polymyxins/Colistin) 
are associated with a smaller reduction in mortality from 
ESBL Pneumonia infections
 
   
 
   
Figure 3: Prior aminoglycoside use has a strong protective 
effect on patient mortality from K. Pneumoniae infection
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